Drug intelligence / Profile preview

FL7729

Development stage: Preclinical
Lead developer: Canget BioTekpharma
Modality: Small Molecules

Overview

FL7729 is a small molecule camptothecin analog currently in preclinical development by Canget BioTekpharma. It is a derivative of FL118, a potent anticancer compound designed to overcome treatment resistance by inhibiting the expression of multiple anti-apoptotic proteins, including survivin, Mcl-1, XIAP, and cIAP2. FL7729 is specifically being investigated for the treatment of retinoblastoma, where it has demonstrated in vitro activity. Like its parent compound, FL7729 is intended to induce apoptosis in cancer cells by suppressing key survival pathways that are often upregulated in solid tumors.

Targets

MDM4 (Mouse double minute X homolog)MCL1 (Myeloid cell leukemia sequence 1)BIRC5 (Survivin)XIAP (Baculoviral IAP repeat-containing protein 4)

Beyond the preview

Go deeper on FL7729.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL7729.

Explore the full profile